Donor cell infusion for high-risk leukemia after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether giving extra donor immune cells (called DLI) after a stem cell transplant can help prevent relapse in people with hard-to-treat myeloid cancers. It may be an option if you had active disease at transplant but then achieved a deep remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stem cell transplant from a donor (not yourself) for a type of blood cancer called acute myeloid leukemia or a high-risk myelodysplastic syndrome.
- Your cancer did not respond to treatment or came back before the transplant. This means more than 5% of cells in your bone marrow were blasts after chemotherapy.
- Within one month after transplant, tests showed no sign of cancer (called MRD-negative remission).
- You are not on dialysis, do not have severe heart or lung problems, and do not have uncontrolled infections or active graft-versus-host disease that is not controlled.
- You have not taken part in another research drug trial in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
This trial tests whether giving donor immune cells after a stem cell transplant can help prevent leukemia from coming back. The donor will do exercise sessions before donating cells to potentially make the treatment more effective.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests a conditioning regimen (total marrow and lymphoid irradiation, fludarabine, and melphalan) before a donor stem cell transplant for people with high-risk myelodysplastic syndrome or acute myeloid leukemia. It aims to reduce side effects while still controlling the disease.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.